Neuroendocrine tumours account for only 0.5% of all malignancies. The incidence is approximately 2/100,000 with a female preponderance under the age of 50 years due to appendiceal location. The main primary sites are the gastrointestinal tract (62–67%) and the lung (22–27%). Presentation with metastatic disease accounts for 12–22%. In the last decades, the incidence has been rising. This might be due to more awareness, improved diagnostic tools or a change in definition. Most neuroendocrine tumours are mainly sporadic, but association with the multiple endocrine neoplasia type 1 syndrome and clustering within families is known. Also an increased risk of secondary cancers has been reported, but numbers are small. The 5-year survival is mainly associated with stage: 93% in local disease, 74% in regional disease and 19% in metastatic disease. In metastatic disease, survival increased since 1992, when treatment with octreotide became largely available in the Netherlands.

1.
Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 1999;40:858–868.
2.
Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH: Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996;14:1829–1838.
3.
Taal BG, Hoefnagel C, Boot H, Valdes Olmos R, Rutgers M: Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol 2000;11:1437–1443.
4.
Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG: Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003;97:1609–1615.
5.
Newton JN, Swerdlow AJ, dos Santos Silva IM, Vessey MP, Grahmae-Smith DG, Primatesta P, Reynolds DJM: The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994;70:939–942.
6.
Westergaard T, Frisch M, Melbye M: Carcinoid tumors in Denmark 1978–1989 and the risk of subsequent cancers. A population-based study. Cancer 1995;76:106–109.
7.
Crocetti E, Buiatti E, Amorosi A: Epidemiology of carcinoid tumours in central Italy. Eur J Epidemiol 1997;13:357–359.
8.
Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C: Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–1997. Br J Cancer 2000;83:952–955.
9.
Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2,391 patients. Ann Oncol 2001;12:1295–1300.
10.
Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 2001;92:2204–2210.
11.
Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934–959.
12.
Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V, Corinaldesi R: Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol 2001;12(suppl 2):S95–S99.
13.
Levi F, Randimbison L, Franceschi S, La Vecchia C: Descriptive epidemiology of malignant carcinoids in the Swiss Canton of Vaud. Int J Cancer 1993;53:1036–1037.
14.
Hemminki K, Li X: Familial carcinoid tumors and subsequent cancers: A nation-wide epidemiologic study from Sweden. Int J Cancer 2001;94:444–448.
15.
Kaerlev L, Teglbjaerg PS, Sabroe S, Kolstad HA, Ahrens W, Eriksson M, et al: Occupational risk factors for small bowel carcinoid tumor: A European population-based case-control study. J Occup Environ Med 2002;44:516–522.
16.
van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM: Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000;10:2186–2187.
17.
Skuladottir H, Hirsch FR, Hansen HH, Olsen JH: Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002;37:127–135.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.